Posted by Michael Wonder on 30 Jul 2024
Alpha Cognition’s oral therapy Zunveyl receives FDA approval to treat Alzheimer's disease
29 July 2024 - The second oral therapy approved this decade, Zunveyl's dual MOA was designed to eliminate drug absorption in the gastro-intestinal tract, potentially addressing certain tolerability issues with leading Alzheimer’s disease medications, combined with a long-term efficacy profile.
Alpha Cognition announces that the US FDA has granted approval for Zunveyl (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild to moderate Alzheimer's disease.
